Healthcare / Medical DevicesShenzhen
$10.21
-0.08 (-0.78%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $60.6M · quality 66.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.7B
P/E
127.6x
↑EV/EBITDA
26.7x
↑ROE
2.7%
↑Gross Margin
27.1%
↓Debt/Equity
0.31
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+17.7%
FCF CAGR
+47.9%
FCF margin
6.1%
FCF / Net income
1.67x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.89B · net income $68.5M · FCF $114.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.89B | $1.89B | $1.56B | $1.47B | $1.16B |
| Net Income | $68.5M | $68.5M | $115.4M | $100.4M | $-595.9M |
| EBITDA | $280.4M | $280.4M | $250.3M | $215.4M | $-501.4M |
| EPS | 0.09 | 0.09 | 0.18 | 0.16 | -1.01 |
| Gross Margin | 27.1% | 27.1% | 25.9% | 28.3% | 26.5% |
| Operating Margin | 12.3% | 12.3% | 10.1% | 11.3% | 10.3% |
| Net Margin | 3.6% | 3.6% | 7.4% | 6.8% | -51.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.31 | 0.31 | 0.14 | 0.22 | 0.09 |
| Current Ratio | 2.21 | 2.21 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $114.2M | $114.2M | $60.6M | $31.8M | $35.3M |
| Returns | |||||
| ROE | 2.7% | 2.7% | 4.7% | 7.3% | -46.4% |
| Valuation | |||||
| P/E | 127.63 | 127.63 | 48.39 | 62.56 | — |
| EV/EBITDA | 26.67 | 26.67 | 18.71 | 28.33 | — |
| P/B | 3.09 | 3.09 | 2.30 | 4.55 | 5.31 |
| Growth & Yield | |||||
| Revenue Growth | 20.9% | 20.9% | 6.0% | 27.2% | — |
| EPS Growth | -50.0% | -50.0% | 12.5% | 115.8% | — |
| Dividend Yield | 0.2% | 0.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
115.9%
EPS terminal req.
$0.91
Spread vs growth
-165.9%
5Y implied EPS CAGR
64.9%
EPS terminal req.
$1.10
Spread vs growth
-114.9%
10Y implied EPS CAGR
34.7%
EPS terminal req.
$1.77
Spread vs growth
-84.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+8.4%
Start / end P/E
52.4x → 113.4x
EPS bridge
0.18 → 0.09
Residual
-58.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.